Comparison of Microvascular Permeability Measurements, K^trans, Determined with Conventional Steady-State T1-Weighted and First-Pass T2*-Weighted MR Imaging Methods in Gliomas and Meningiomas

References

1. ↵
   Provenzale JM, Wang GR, Brenner T, et al. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 2002;178:711–16

   CrossRefPubMedWeb of Science
2. Stewart PA, Hayakawa K, Farrell CL, et al. Quantitative study of microvessel ultrastructure in human peritumoral brain tissue: evidence for a blood-brain barrier defect. J Neurosurg 1987;67:697–705

   PubMedWeb of Science
3. Uematsu H, Maeda M, Sadato N, et al. Vascular permeability: quantitative measurement with double-echo dynamic MR imaging: theory and clinical application. Radiology 2000;214:912–17

   PubMed
4. ↵
   Yang S, Law M, Zagzag D, et al. Dynamic contrast-enhanced perfusion MR imaging measurements of endothelial permeability: differentiation between atypical and typical meningiomas. AJNR Am J Neuroradiol 2003;24:1554–59

   Abstract/FREE Full Text
5. ↵
   Law M, Yang S, Babb JS, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004;25:746–55

   Abstract/FREE Full Text
6. ↵
   Roberts HC, Roberts TP, Brasch RC, et al. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000;21:891–99

   Abstract/FREE Full Text
7. ↵
   Roberts HC, Roberts TP, Ley S, et al. Quantitative estimation of microvascular permeability in human brain tumors: correlation of dynamic Gd-DTPA-enhanced MR imaging with histopathologic grading. Acad Radiol 2002;9(suppl 1):S151–55
8. ↵
   Tofts PS, Brix G, Buckly DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223–32

   CrossRefPubMedWeb of Science
9. ↵
   Harrer JU, Parker GJ, Haroon HA, et al. Comparative study of methods for determining vascular permeability and blood volume in human gliomas. J Magn Reson Imaging 2004;20:748–57

   CrossRefPubMed
10. ↵
    Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991;17:357–67

    CrossRefPubMedWeb of Science
11. ↵
    Buckley DL. Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI. Magn Reson Med 2002;47:601–06

    CrossRefPubMedWeb of Science
12. ↵
    Johnson G, Wetzel SG, Cha S, et al. Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI. Magn Reson Med 2004;51:961–68

    CrossRefPubMed
13. ↵
    Surawicz TS, McCarthy BJ, Kupelian V, et al. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990–1994. Neurooncol 1999;1:14–25

    Abstract/FREE Full Text
14. ↵
    Dowd CF, Halbach VV, Higashida RT. Meningiomas: the role of preoperative angiography and embolization. Neurosurg Focus 2003;15:E10

    PubMed
15. ↵
    Kleihues P, Soylemezoglu F, Schauble B, et al. Histopathology, classification, and grading of gliomas. Glia 1995;15:211–21

    CrossRefPubMedWeb of Science
16. ↵
    Bergsland EFL, Meropol HJ, Gaudreault J, et al. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000;242a
17. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC [ASCO meeting, abstract 3646]. Proc Am Soc Clin Oncol 2003;22:906
18. ↵
    Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60–65

    Abstract/FREE Full Text
19. ↵
    Tofts PS, Barker GJ, Filippi M, et al. An oblique cylinder contrast-adjusted (OCCA) phantom to measure the accuracy of MRI brain lesion volume estimation schemes in multiple sclerosis. Magn Reson Imaging 1997;15:183–92

    CrossRefPubMedWeb of Science
20. ↵
    Roberts HC, Roberts TP, Bollen AW, et al. Correlation of microvascular permeability derived from dynamic contrast-enhanced MR imaging with histologic grade and tumor labeling index: a study in human brain tumors. Acad Radiol 2001;8:384–91

    CrossRefPubMed
21. ↵
    George ML, Dzik-Jurasz AS, Padhani AR, et al. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg 2001;88:1628–36

    CrossRefPubMedWeb of Science
22. ↵
    Knopp MV, Giesel FL, Marcos H, et al. Dynamic contrast-enhanced magnetic resonance imaging in oncology. Top Magn Reson Imaging 2001;12:301–08

    CrossRefPubMed
23. ↵
    Li KL, Zhu XP, Checkley DR, et al. Simultaneous mapping of blood volume and endothelial permeability surface area product in gliomas using iterative analysis of first-pass dynamic contrast enhanced MRI data. Br J Radiol 2003;76:39–50

    Abstract/FREE Full Text
24. ↵
    Hakyemez B, Erdogan C, Ercan I, et al. High-grade and low-grade gliomas: differentiation by using perfusion MR imaging. Clin Radiol 2005;60:493–502

    CrossRefPubMed
25. ↵
    Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989–98

    Abstract/FREE Full Text
26. ↵
    Cha S, Tihan T, Crawford F, et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2005;26:266–73

    Abstract/FREE Full Text
27. ↵
    Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendroglimoas. AJNR Am J Neuroradiol 2004;25:214–21

    Abstract/FREE Full Text
28. ↵
    Bian XW, Du LL, Shi JQ, et al. Correlation of bFGF, FGFR-1 and VEGF expression with vascularity and malignancy of human astrocytomas. Anal Quant Cytol Histol 2000;22:267–74

    PubMed
29. ↵
    Chaudhry IH, O’Donovan DG, Brenchley PE, et al. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 2001;39:409–15

    CrossRefPubMedWeb of Science
30. ↵
    Zhu XP, Li KL, Kamaly-Asl ID, et al. Quantification of endothelial permeability, leakage space, and blood volume in brain tumors using combined T1 and T2* contrast-enhanced dynamic MR imaging. J Magn Reson Imaging 2000;11:575–85

    CrossRefPubMedWeb of Science
31. ↵
    Barbier EL, den Boer JA, Peters AR, et al. A model of the dual effect of gadopentetate dimeglumine on dynamic brain MR images. J Magn Reson Imaging 1999;10:242–53

    CrossRefPubMed
32. ↵
    Ostergaard L, Hochberg FH, Rabinov JD, et al. Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors. J Neurosurg 1999;90:300–05

    PubMedWeb of Science